Literature DB >> 21955569

The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors.

Junzo Hamanishi1, Masaki Mandai, Kaoru Abiko, Noriomi Matsumura, Tsukasa Baba, Yumiko Yoshioka, Kenzo Kosaka, Ikuo Konishi.   

Abstract

The aim of this study was to evaluate the local immune status of human ovarian cancers by the comprehensive analysis of tumor-infiltrating immune cells and immunosuppressive factors, and to elucidate the local immunity in clinical course. The numbers of CD1α+, CD4+, CD8+, CD57+, forkhead box P3+ and programmed cell death-1+ cells were counted, and the intensity of immunosuppressive factors, such as programmed cell death-1 ligand (PD-L)1, PD-L2, cyclooxygenase (COX)-1, COX-2 and transforming growth factor β1, were evaluated in 70 ovarian cancer specimens stained by immunohistochemistry. Then hierarchical clustering of these parameters showed the four clusters into ovarian cancer cases. Cluster 1, which had significantly better prognosis than the others, was characterized by high infiltration of CD4+ and CD8+ cells. In conclusion the comprehensive analysis of local immune status led to subdivide ovarian cancers into groups with better or worse prognoses and may guide precise understanding of the local immunity.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21955569     DOI: 10.1016/j.clim.2011.08.013

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  34 in total

Review 1.  Tumor infiltrating lymphocytes in ovarian cancer.

Authors:  Phillip P Santoiemma; Daniel J Powell
Journal:  Cancer Biol Ther       Date:  2015-04-20       Impact factor: 4.742

2.  An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia.

Authors:  Natsuki Nakagawa; Yoshiko Hashii; Hisako Kayama; Ryu Okumura; Hiroko Nakajima; Hikaru Minagawa; Soyoko Morimoto; Fumihiro Fujiki; Jun Nakata; Toshiro Shirakawa; Takane Katayama; Kiyoshi Takeda; Akihiro Tsuboi; Keiichi Ozono
Journal:  Cancer Immunol Immunother       Date:  2022-06-14       Impact factor: 6.968

Review 3.  Dynamic host immunity and PD-L1/PD-1 blockade efficacy: developments after "IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer".

Authors:  Kaoru Abiko; Junzo Hamanishi; Noriomi Matsumura; Masaki Mandai
Journal:  Br J Cancer       Date:  2022-09-06       Impact factor: 9.075

4.  Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer.

Authors:  Ganga Gopinathan; Chiara Berlato; Anissa Lakhani; Ludmila Szabova; Colin Pegrum; Ana-Rita Pedrosa; Florian Laforets; Eleni Maniati; Frances R Balkwill
Journal:  Mol Cancer Ther       Date:  2022-06-01       Impact factor: 6.009

5.  Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.

Authors:  Mario Sznol; Lieping Chen
Journal:  Clin Cancer Res       Date:  2013-03-01       Impact factor: 12.531

6.  A new antisarcoma strategy: multisubtype heat shock protein/peptide immunotherapy combined with PD-L1 immunological checkpoint inhibitors.

Authors:  H Li; X Sui; Z Wang; H Fu; Z Wang; M Yuan; S Liu; G Wang; Q Guo
Journal:  Clin Transl Oncol       Date:  2021-04-01       Impact factor: 3.405

7.  IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.

Authors:  K Abiko; N Matsumura; J Hamanishi; N Horikawa; R Murakami; K Yamaguchi; Y Yoshioka; T Baba; I Konishi; M Mandai
Journal:  Br J Cancer       Date:  2015-03-31       Impact factor: 7.640

8.  Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity.

Authors:  Nune Markosyan; Edward P Chen; Rebecca A Evans; Victoire Ndong; Robert H Vonderheide; Emer M Smyth
Journal:  Breast Cancer Res       Date:  2013       Impact factor: 6.466

9.  Immunosuppression through constitutively activated NF-κB signalling in human ovarian cancer and its reversal by an NF-κB inhibitor.

Authors:  H Nishio; T Yaguchi; J Sugiyama; H Sumimoto; K Umezawa; T Iwata; N Susumu; T Fujii; N Kawamura; A Kobayashi; J Park; D Aoki; Y Kawakami
Journal:  Br J Cancer       Date:  2014-05-27       Impact factor: 7.640

10.  Intratumoral CD8⁺ cytotoxic lymphocyte is a favorable prognostic marker in node-negative breast cancer.

Authors:  Zonglin Chen; Xianyu Chen; Enxiang Zhou; Ganlong Chen; Ke Qian; Xia Wu; Xiongying Miao; Zhonghua Tang
Journal:  PLoS One       Date:  2014-04-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.